



Course Videos
Although triploidy is one of the most common chromosome abnormalities identified in human conceptions, why does the counting methodology fail to detect triploidy?
Why does utilization of NIPT in place of MSS reduce the number of women who receive a false positive screening result and the associated anxiety? Please explain why the accuracy of these tests differ.
How does SNP-based NIPT compare to maternal serum screening (MSS) with respect to sensitivity, specificity, false negative rates, false positive rates, and positive predictive value (PPV) in a real world patient population?
How does SNP-based NIPT technology offer distinct advantages for NIPT?
How does SNP-based NIPT technology offer distinct advantages for NIPT?
How will the evaluation of cffDNA change the approach to prenatal screening for genetic disorders beyond the common aneuploidies in the future? Does this approach deserve widespread application across multiple risk groups, and if so, why?
How has NIPT progressed from first to second generation testing? And what specific delineation does the evolution to SNP-based testing make possible?
How has NIPT changed the landscape of prenatal testing? And what are the specific advantages that accrue to patients who undergo NIPT?
How and when was NIPT first implemented in prenatal screening? And why is this test essential for an accurate evaluation of the pregnant patient at multiple levels of risk?
What impact do the results of carrier screening have on non-health related issues and affordability?
What impact do the results of carrier screening have on non-health related issues and affordability?
How often do we encounter false-positive and false-negative results and how do we determine positive predictive value?
Is it appropriate to offer concurrent patient/partner carrier screening?
Is it appropriate to offer concurrent patient/partner carrier screening?
Are all expanded carrier screenings the same? How do these technologies differ? What screening technology do you use and why?